Top

Annals of Hematology

Published in:

01-06-2018 | Letter to the Editor

The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma

Authors: Takahiro Kobayashi, Masatomo Miura, Maiko Abumiya, Takenori Niioka, Shuichi Kanno, Naoto Takahashi

Published in: Annals of Hematology | Issue 6/2018

Excerpt

Dear Editor, …

Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle P, Pearse R, Chen-Kiang S, Coleman M, Niesvizky R (2013) BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood 121(11):1982–1985. https://doi.org/10.1182/blood-2012-08-448563 CrossRefPubMedPubMedCentral

Niesvizky R, Bergsagel PL, Pearse RN, Pekle K A, Lyons LM, Cho HJ, Roboz GJ, Leonard JP, Coleman M (2002) Clarithromycin potentiates the response to dexamethasone in chemotherapy naive multiple myeloma patients: a prospective, sequential, randomized trial. [Abstract] Blood (100) 389b

Spahn JD, Fost DA, Covar R, Martin RJ, Brown EE, Szefler SJ, Leung DY (2001) Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 87(6):501–505. https://doi.org/10.1016/S1081-1206(10)62264-8 CrossRefPubMed

Hofmeister CC, Yang X, Pichiorri F, Chen P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, Ji J, Schaaf LJ, Benso Jr DM, Kraut EH, Hicks WJ, Chan KK, Chen C-S, Farag SS, Grever MR, Byrd JC, Phelps MA (2011) Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide–CCI-779 interaction via P-glycoprotein. J Clin Oncol 29(25):3427–3434. https://doi.org/10.1200/JCO.2010.32.4962 CrossRefPubMedPubMedCentral

Takahashi N, Miura M, Kameoka Y, Abumiya M, Sawada K (2012) Drug interaction between lenalidomide and itraconazole. Am J Hematol 87(3):338–333. https://doi.org/10.1002/ajh.22260 CrossRefPubMed

Miura M, Takahashi N, Kanno S, Kato S, Nara M, Itoh M, Saitoh H, Yoshioka T, Kameoka Y, Fujisjima N, Tagawa H, Hirokawa M, Sawada K (2011) Drug interaction of (S)-warfarin, and not (R)-warfarin, with itraconazole in a hematopoietic stem cell transplant recipient. Clin Chim Acta 412(21):2002–2006. https://doi.org/10.1016/j.cca.2011.06.035 CrossRefPubMed

Shida S, Takahashi N, Miura M, Niioka T, Matsumoto M, Hagihara M, Kobayashi T, Abumiya M, Kameoka Y, Fujishima N, Tagawa H, Hirokawa M, Sawada K (2014) A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients. Ther Drug Monit 36(4):505–509. https://doi.org/10.1097/FTD.0000000000000034 CrossRefPubMed

Title: The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma
Authors: Takahiro Kobayashi
Masatomo Miura
Maiko Abumiya
Takenori Niioka
Shuichi Kanno
Naoto Takahashi
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 6/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3270-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2018

Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation

Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review

Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents—a single centre experience of 20 years

Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy

Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG

Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page